Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA

Transgenic Research

Volumn 20, Issue 6, 2011, Pages 1293-1304

  Lorson, Monique A ^a   Spate, Lee D ^a   Samuel, Melissa S ^a   Murphy, Clifton N ^a   Lorson, Christian L ^a,b   Prather, Randall S ^a   Wells, Kevin D ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

Animal model; For gene therapy; Neurodegenerative disease; Spinal Muscular Atrophy (SMA); Transgenic pigs

Indexed keywords

SINGLE STRANDED DNA; SMN1 PROTEIN, HUMAN; SMN2 PROTEIN, HUMAN; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2;

ANIMAL; ARTICLE; DISEASE MODEL; ELECTROPORATION; EMBRYO CULTURE; FEMALE; GENE INACTIVATION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HELA CELL; HUMAN; MALE; METABOLISM; MOLECULAR CLONING; PREGNANCY; RNA SPLICING; SOUTHERN BLOTTING; SPINAL MUSCULAR ATROPHY; SWINE; TRANSGENE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOTTING, SOUTHERN; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; DNA, SINGLE-STRANDED; ELECTROPORATION; EMBRYO CULTURE TECHNIQUES; FEMALE; GENE KNOCKOUT TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; MALE; MUSCULAR ATROPHY, SPINAL; PREGNANCY; RNA SPLICING; SURVIVAL OF MOTOR NEURON 1 PROTEIN; SURVIVAL OF MOTOR NEURON 2 PROTEIN; SWINE; TRANSFECTION; TRANSGENES;

ANIMALIA; SUIDAE; SUS;

EID: 80855144747     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-011-9496-8     Document Type: Article

References (51)

1. Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, Chen X, Whitney M, Pollok B, Zhang M, Androphy E et al (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10: 2841-2849.
2. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, Villanova M, Bertini E, Pini A, Neri G et al (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12: 59-65.
3. Baughan T, Shababi M, Coady TH, Dickson AM, Tullis GE, Lorson CL (2006) Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol Ther 14: 54-62.
4. Baughan TD, Dickson A, Osman EY, Lorson CL (2009) Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet 18: 1600-1611.
5. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489.
6. Butchbach ME, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, Thurmond J, Andresson T, Zhang J, Edwards JD, Simard LR et al (2010) Effects of 2, 4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 19: 454-467.
7. Cartegni L, Krainer AR (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30: 377-384.
8. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 98: 9808-9813.
9. Coady TH, Lorson CL (2010) Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J Neurosci 30: 126-130.
10. Coady TH, Baughan TD, Shababi M, Passini MA, Lorson CL (2008) Development of a single vector system that enhances trans-splicing of SMN2 transcripts. PLoS One 3: e3468.
11. Dai Y, Vaught TD, Boone J, Chen SH, Phelps CJ, Ball S, Monahan JA, Jobst PM, McCreath KJ, Lamborn AE et al (2002) Targeted disruption of the alpha 1, 3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 20: 251-255.
12. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, de Moura AP, Voit T, Barkats M (2011) Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20: 681-693.
13. Elsheikh B, Prior T, Zhang X, Miller R, Kolb SJ, Moore D, Bradley W, Barohn R, Bryan W, Gelinas D et al (2009) An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40: 652-656.
14. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH et al (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
15. Geib T, Hertel KJ (2009) Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS One 4: e8204.
16. Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, Barthel L, Kumar S, Dudley C, Nelson M, Larson K et al (2009) Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med 1: 5ra12.
17. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H (2000) A mouse model for spinal muscular atrophy. Nat Genet 24: 66-70.
18. Hua Y, Vickers T, Okunola H, Bennett C, Krainer, A (2008) Antisense masking of an hnRNP A1/A2 intronic splice silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82: 834-848.
19. Hua Y, Sahaski K, Hung G, Rigo F, Passini M, Bennett C, Krainer A (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24: 1634-1644.
20. Lai L, Prather RS (2003) Creating genetically modified pigs by using nuclear transfer. Reprod Biol Endocrinol 1: 82.
21. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im GS, Samuel M, Bonk A, Rieke A, Day BN et al (2002) Production of alpha-1, 3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295: 1089-1092.
22. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, Bassell GJ, Burghes AH (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14: 845-857.
23. Lim SR, Hertel KJ (2001) Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem 276: 45476-45483.
24. Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96: 6307-6311.
25. Lorson MA, Spate LD, Prather RS, Lorson CL (2008) Identification and characterization of the porcine (Sus scrofa) survival motor neuron (SMN1) gene: an animal model for therapeutic studies. Dev Dyn 237: 2268-2278.
26. Lorson CL, Rindt H, Shababi M (2010) Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet 19: 111-118.
27. Machaty Z, Wang WH, Day BN, Prather RS (1997) Complete activation of porcine oocytes induced by the sulfhydryl reagent, thimerosal. Biol Reprod 57: 1123-1127.
28. MacKenzie A (2010) Genetic therapy for spinal muscular atrophy. Nat Biotechnol 28: 235-237.
29. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ (2005) Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther 12: 1013-1022.
30. Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL (2006) Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 120: 589-601.
31. Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL (2009a) Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum Mol Genet 18: 3906-3913.
32. Mattis VB, Fosso MY, Chang CW, Lorson CL (2009b) Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA. BMC Neurosci 10: 142.
33. Michaud M, Arnoux T, Bielli S, Durand E, Rotrou Y, Jablonka S, Robert F, Giraudon-Paoli M, Riessland M, Mattei MG et al (2010) Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol Dis 38: 125-135.
34. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8: 1177-1183.
35. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, Jablonka S, Schrank B, Rossol W, Prior TW et al (2000) The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9: 333-339.
36. Monani UR, Pastore MT, Gavrilina TO, Jablonka S, Le TT, Andreassi C, DiCocco JM, Lorson C, Androphy EJ, Sendtner M et al (2003) A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol 160: 41-52.
37. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR, Klinger KW, Shihabuddin LS, Cheng SH (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120: 1253-1264.
38. Prior TW (2010) Perspectives and diagnostic considerations in spinal muscular atrophy. Genet Med 12: 145-152.
39. Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgman SJ, Burghes AH, Kissel JT (2009) A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet 85: 408-413.
40. Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E et al (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 19: 1492-1506.
41. Ross JW, Whyte JJ, Zhao J, Samuel M, Wells KD, Prather RS (2010) Optimization of square-wave electroporation for transfection of porcine fetal fibroblasts. Transgenic Res 19: 611-620.
42. Schrank B, Gotz R, Gunnersen JM, Ure JM, Toyka KV, Smith AG, Sendtner M (1997) Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 94: 9920-9925.
43. Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN (2009) A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 6: 341-350.
44. Stavarachi M, Apostol P, Toma M, Cimponeriu D, Gavrila L (2010) Spinal muscular atrophy disease: a literature review for therapeutic strategies. J Med Life 3: 3-9.
45. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, Schussler K, Chen X, Jarecki J, Burghes AH et al (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54: 647-654.
46. Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M et al (2008) Synthesis and biological evaluation of novel 2, 4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J Med Chem 51: 449-469.
47. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, Azzouz M (2010) Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2: 35ra42.
48. Wirth B (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 15: 228-237.
49. Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL (2005) A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 14: 1199-1210.
50. Zhang ML, Lorson CL, Androphy EJ, Zhou J (2001) An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 8: 1532-1538.
51. Zhao J, Ross JW, Hao Y, Spate LD, Walters EM, Samuel MS, Rieke A, Murphy CN, Prather RS (2009) Significant improvement in cloning efficiency of an inbred miniature pig by histone deacetylase inhibitor treatment after somatic cell nuclear transfer. Biol Reprod 81: 525-530.